Biotechnology Assets Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Biotechnology Assets has been growing earnings at an average annual rate of 49.7%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 34% per year.
Belangrijke informatie
49.7%
Groei van de winst
56.5%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | -7.2% |
| Inkomstengroei | -34.0% |
| Rendement op eigen vermogen | -42.2% |
| Nettomarge | -90.5% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Opbrengsten en kosten
Hoe Biotechnology Assets geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 3 | -3 | 3 | 0 |
| 31 Mar 24 | 4 | -1 | 3 | 0 |
| 31 Dec 23 | 4 | 2 | 3 | 0 |
| 30 Sep 23 | 4 | 2 | 3 | 0 |
| 30 Jun 23 | 3 | 3 | 3 | 0 |
| 31 Mar 23 | 3 | 0 | 3 | 0 |
| 31 Dec 22 | 3 | -2 | 3 | 0 |
| 30 Sep 22 | 3 | -2 | 3 | 0 |
| 30 Jun 22 | 3 | -2 | 3 | 0 |
| 31 Mar 22 | 3 | -3 | 3 | 0 |
| 31 Dec 21 | 3 | -3 | 3 | 0 |
| 30 Sep 21 | 3 | -3 | 3 | 0 |
| 30 Jun 21 | 3 | -2 | 3 | 0 |
| 31 Mar 21 | 3 | -2 | 3 | 0 |
| 31 Dec 20 | 3 | -2 | 2 | 0 |
| 30 Jun 20 | -17 | -2 | -9 | 0 |
| 31 Mar 20 | -7 | -2 | -2 | 0 |
| 31 Dec 19 | 3 | -3 | 4 | 0 |
| 30 Sep 19 | 41 | -11 | 30 | 0 |
| 30 Jun 19 | 38 | -11 | 29 | 0 |
| 31 Mar 19 | 31 | -14 | 28 | 0 |
| 31 Dec 18 | 25 | -17 | 27 | 0 |
| 30 Sep 18 | 21 | -15 | 24 | 0 |
| 30 Jun 18 | 16 | -14 | 20 | 0 |
| 31 Mar 18 | 15 | -13 | 18 | 0 |
| 31 Dec 17 | 13 | -12 | 17 | 0 |
| 31 Dec 16 | 6 | -3 | 8 | 0 |
| 31 Dec 15 | 5 | -8 | 6 | 0 |
Kwaliteitswinsten: BST is currently unprofitable.
Groeiende winstmarge: BST is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: BST is unprofitable, but has reduced losses over the past 5 years at a rate of 49.7% per year.
Versnelling van de groei: Unable to compare BST's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: BST is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).
Rendement op eigen vermogen
Hoge ROE: BST has a negative Return on Equity (-42.24%), as it is currently unprofitable.